Medical device and technologies product provider C.R. Bard (NYSE:BCR) has posted steady, albeit modest growth trends over the last decade or so. Its founding goes back more than a century and provides sales and profit stability with a certain amount of downside protection. However, the richer valuation could handicap future upside potential.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

First Quarter Recap
Sales improved 4% to $730 million. Sales in the United States accounted for 68% of the top line and improved a modest but respectable 2%. International sales made up the rest and grew a healthy 10%, with currency fluctuations dragging down the reported total by a single percentage point. Bard also breaks its sales up by four primary operating segments. Oncology (catheters, feeding devices) was the strongest performer and reported 7% growth to account for 27.2% of total sales. Vascular (heart products such as stents and grafts), the largest segment at 28.7% of the quarterly total, reported a 5% growth. Urology (catheters and stents - 25.3% of total sales) logged a modest 3% growth while surgical specialties (soft tissue meshes and patches) were flat at 15.7% of sales. The "other" category accounted for the rest of the top line and grew 4%.

Pretax income also improved 4% to $191.4 million as cost growth kept pace with the sales expansion. Slightly lower tax expense growth resulted in net income growth of 5.2% to $138.7 million, or $1.60 per diluted share.

SEE: Understanding The Income Statement

Outlook and Valuation
For the year, analysts' project sales growth of almost 5% and total sales just over $3 billion. The consensus earnings projection currently stands at $6.67 which, when taking the current stock price of $98 per share, equates to a forward P/E of 14. This is below Bard's five-year average above 20, which is also the industry average. Rivals include Covidien (NYSE:COV), Becton Dickinson (NYSE:BDX), Boston Scientific (NYSE:BSX) and Teleflex (NYSE:TFX), with only Teleflex smaller in terms of sales over the past year.

The Bottom Line
Over the past decade, Bard has grown both sales and earnings at around 10% annually. Growth has slowed to the high single digits over the past five years on average, but international growth has the potential to boost overall trends as it continues to account for a higher proportion of the total top line.

The stock looks pricey based on the P/E, but is less so when looking at cash flow. Last year, Bard operated approximately $7.26 per share in free cash flow, for a trailing cash flow multiple of 13.5. Overall though, this is still a rich multiple given the modest operational growth. On the flip side, there is ample downside protection as product demand is relatively recession resistant.

SEE: 5 Must-Have Metrics For Value Investors

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  2. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  3. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  4. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  5. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  6. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  7. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  8. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  9. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  10. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!